From: Junctional bradycardia is a potential risk factor of stroke
JB group (n = 69) | Control group (n = 138) | P value* | JB with P group (n = 24) | JB without P group (n = 45) | P value** | |
---|---|---|---|---|---|---|
Age (years) | 68.5 ± 16.5 | 68.4 ± 15.7 | 0.593 | 67.3 ± 16.6 | 69.2 ± 16.5 | 0.273 |
Men, n (%) | 35 (50.7) | 72 (52.2) | 0.883 | 10 (41.7) | 25 (55.6) | 0.318 |
Smoking, n (%) | 26 (37.7) | 40 (29.0) | 0.210 | 8 (33.3) | 18 (40.0) | 0.614 |
Hypertension, n (%) | 39 (56.5) | 76 (55.1) | 0.883 | 11 (45.8) | 28 (62.2) | 0.213 |
Diabetes mellitus, n (%) | 30 (43.5) | 50 (36.2) | 0.364 | 8 (33.3) | 22 (48.9) | 0.308 |
Heart failure, n (%) | 6 (8.7) | 11 (8.0) | >0.999 | 3 (12.5) | 3 (6.7) | 0.412 |
Chronic kidney disease, n (%) | 20 (29.0) | 22 (15.9) | 0.043 | 5 (20.8) | 15 (33.3) | 0.404 |
History of CAD, n (%) | 21 (30.4) | 44 (31.9) | 0.875 | 3 (12.5) | 18 (40.0) | 0.027 |
History of stroke, n (%) | 1 (1.4) | 1 (0.7) | >0.999 | 0 (0.0) | 1 (2.2) | >0.999 |
Ejection fraction (%) | 64.2 ± 11.3 | 63.3 ± 11.0 | 0.485 | 63.8 ± 13.4 | 64.4 ± 10.1 | 0.772 |
LAVI (ml/m2) | 45.1 ± 30.3 | 28.0 ± 11.3 | 0.001 | 40.8 ± 10.4 | 47.1 ± 36.1 | 0.740 |
Antiplatelet agents, n (%) | 33 (47.8) | 101 (73.2) | 0.883 | 9 (37.5) | 24 (53.3) | 0.312 |
Statin, n (%) | 26 (37.7) | 52 (37.7) | >0.999 | 7 (29.2) | 19 (42.2) | 0.312 |
Anticoagulants, n (%) | 8 (11.6) | 6 (4.3) | 0.091 | 2 (8.3) | 6 (13.3) | 0.704 |
CHADS2 score | 1.48 ± 1.16 | 1.49 ± 1.19 | 0.991 | 1.17 ± 1.13 | 1.64 ± 1.15 | 0.103 |
0, n (%) | 16 (23.2) | 32 (23.2) | 8 (33.3) | 8 (17.8) | ||
1, n (%) | 22 (31.9) | 44 (31.9) | 8 (33.3) | 14 (31.1) | ||
2, n (%) | 16 (23.2) | 32 (23.2) | 5 (20.8) | 11 (24.4) | ||
3, n (%) | 12 (17.4) | 24 (17.4) | 2 (8.3) | 10 (22.2) | ||
4, n (%) | 3 (4.3) | 6 (4.3) | 1 (4.2) | 2 (4.4)) | ||
Follow-up duration (month) | 27.2 ± 26.2 | 25.4 ± 21.5 | 0.948 | 39.3 ± 36.5 | 20.7 ± 15.6 | 0.008 |